Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liposome bupivacaine · 1 trial · 1 indication
Pain rating (NRS) at rest and with movement
Modified BRIEF Pain Inventory (Q1)
| Arm | Type | Description |
|---|---|---|
| Single mixture LB & bupivacaine | EXPERIMENTAL | A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves |
| Bupivacaine alone | ACTIVE_COMPARATOR | Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves |
| General anesthesia | SHAM_COMPARATOR | General anesthesia |
| Name | Type | Description |
|---|---|---|
| Liposome bupivacaine | DRUG | - |
Inclusion Criteria: * Male or female, at least 18 years and max 65 years of age at screening * Scheduled to undergo primary Scarf osteotomy for elective hallux valgus * American Society of Anesthesiologists (ASA) physical status 1, 2, or 3 * Female subject must be surgically sterile or have a monog...
Liposome bupivacaine is an investigational drug being studied for use in Hallux Valgus (Bunions) and Dupuytren's Contracture of the Hand (Viking's Disease). It is a small molecule being developed by Pacira BioSciences, Inc. for these indications.
Liposome bupivacaine is a small molecule. Its specific molecular target has not been disclosed in the available information.
Liposome bupivacaine is being developed by Pacira BioSciences, Inc., a company traded under the ticker symbol PCRX.
Liposome bupivacaine is in Phase 2 clinical development. It is investigational and has not been approved by regulatory authorities.
Liposome bupivacaine has been studied in two completed Phase 2 trials. NCT03106519 evaluated it for Dupuytren's Contracture of the Hand, and NCT03106545 evaluated it for Hallux Valgus (Bunions). Both trials were conducted in Belgium.
Liposome bupivacaine is a formulation of bupivacaine, but it is not the same as standard bupivacaine. The liposome formulation is designed to provide extended release of the drug.